Literature DB >> 18316398

A tale of two Cbls: interplay of c-Cbl and Cbl-b in epidermal growth factor receptor downregulation.

Steven Pennock1, Zhixiang Wang.   

Abstract

The precise role of Cbl in epidermal growth factor (EGF) receptor (EGFR) endocytosis and trafficking remains to be fully uncovered. Here, we showed that mutant EGFR1044, which was truncated after residue 1044, did not associate with c-Cbl and was not ubiquitinated initially in response to EGF but was internalized with kinetics similar to those of wild-type EGFR. This finding indicates that c-Cbl-mediated ubiquitination is not required for EGF-induced EGFR endocytosis. We also showed that the previously identified internalization-deficient mutant receptor EGFR1010LL/AA bound to c-Cbl and was fully ubiquitinated in response to EGF, which indicates that c-Cbl binding and ubiquitination are not sufficient for EGFR internalization. We next investigated EGFR trafficking following EGFR internalization. We found that c-Cbl disassociation from EGFR occurred well in advance of EGFR degradation and that this event was concurrent with the selective dephosphorylation of EGFR at Y1045. This finding suggests that once EGFR is ubiquitinated, continual Cbl association is not required for EGFR degradation. Because EGFR1044 is ubiquitinated and degraded similarly to wild-type EGFR, we examined the role of another prominent Cbl homologue, Cbl-b, and found that Cbl-b was associated with both EGFR and EGFR1044. Further study showed that Cbl-b bound to EGFR at two regions: one in the C-terminal direction from residue 1044 and one in the N-terminal direction from residue 958. Moreover, Cbl-b association with EGFR rose markedly following a decrease in c-Cbl association, corresponding to a second peak of EGFR ubiquitination occurring later in EGFR trafficking. Using RNA interference to knock down both c-Cbl and Cbl-b, we were able to abolish EGFR downregulation. This knockdown had no affect on the rate of EGF-induced EGFR internalization. We found that the two Cbls accounted for total receptor ubiquitination and that while c-Cbl and Cbl-b are each alone sufficient to effect EGFR degradation, both are involved in the physiological, EGF-mediated process of receptor downregulation. Furthermore, these data ultimately reveal a previously unacknowledged temporal interplay of two major Cbl homologues with the trafficking of EGFR.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18316398      PMCID: PMC2293090          DOI: 10.1128/MCB.01809-07

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  58 in total

1.  Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases.

Authors:  N Zheng; P Wang; P D Jeffrey; N P Pavletich
Journal:  Cell       Date:  2000-08-18       Impact factor: 41.582

2.  RING finger mutations that abolish c-Cbl-directed polyubiquitination and downregulation of the EGF receptor are insufficient for cell transformation.

Authors:  C B Thien; F Walker; W Y Langdon
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

3.  The evolutionarily conserved N-terminal region of Cbl is sufficient to enhance down-regulation of the epidermal growth factor receptor.

Authors:  N L Lill; P Douillard; R A Awwad; S Ota; M L Lupher; S Miyake; N Meissner-Lula; V W Hsu; H Band
Journal:  J Biol Chem       Date:  2000-01-07       Impact factor: 5.157

4.  cbl-b inhibits EGF-receptor-induced apoptosis by enhancing ubiquitination and degradation of activated receptors.

Authors:  S A Ettenberg; Y R Rubinstein; P Banerjee; M M Nau; M M Keane; S Lipkowitz
Journal:  Mol Cell Biol Res Commun       Date:  1999-08

5.  Interactions of Cbl with two adapter proteins, Grb2 and Crk, upon T cell activation.

Authors:  L Buday; A Khwaja; S Sipeki; A Faragó; J Downward
Journal:  J Biol Chem       Date:  1996-03-15       Impact factor: 5.157

6.  Cbl-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex.

Authors:  S A Ettenberg; A Magnifico; M Cuello; M M Nau; Y R Rubinstein; Y Yarden; A M Weissman; S Lipkowitz
Journal:  J Biol Chem       Date:  2001-05-24       Impact factor: 5.157

7.  Polyubiquitination of the epidermal growth factor receptor occurs at the plasma membrane upon ligand-induced activation.

Authors:  E Stang; L E Johannessen; S L Knardal; I H Madshus
Journal:  J Biol Chem       Date:  2000-05-05       Impact factor: 5.157

Review 8.  Cbl: many adaptations to regulate protein tyrosine kinases.

Authors:  C B Thien; W Y Langdon
Journal:  Nat Rev Mol Cell Biol       Date:  2001-04       Impact factor: 94.444

9.  c-Cbl ubiquitinates the EGF receptor at the plasma membrane and remains receptor associated throughout the endocytic route.

Authors:  A A de Melker; G van der Horst; J Calafat; H Jansen; J Borst
Journal:  J Cell Sci       Date:  2001-06       Impact factor: 5.285

10.  Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies.

Authors:  Karianne E Longva; Froydis D Blystad; Espen Stang; Astrid M Larsen; Lene E Johannessen; Inger H Madshus
Journal:  J Cell Biol       Date:  2002-02-25       Impact factor: 10.539

View more
  42 in total

1.  In situ analysis of tyrosine phosphorylation networks by FLIM on cell arrays.

Authors:  Hernán E Grecco; Pedro Roda-Navarro; Andreas Girod; Jian Hou; Thomas Frahm; Dina C Truxius; Rainer Pepperkok; Anthony Squire; Philippe I H Bastiaens
Journal:  Nat Methods       Date:  2010-05-09       Impact factor: 28.547

2.  SH3KBP1-binding protein 1 prevents epidermal growth factor receptor degradation by the interruption of c-Cbl-CIN85 complex.

Authors:  Lifeng Feng; Jin-Tao Wang; Hongchuan Jin; Kaixian Qian; Jian-Guo Geng
Journal:  Cell Biochem Funct       Date:  2011-08-09       Impact factor: 3.685

3.  Biochemical, Biophysical and Cellular Techniques to Study the Guanine Nucleotide Exchange Factor, GIV/Girdin.

Authors:  Pradipta Ghosh; Nicolas Aznar; Lee Swanson; I-Chung Lo; Inmaculada Lopez-Sanchez; Jason Ear; Cristina Rohena; Nicholas Kalogriopoulos; Linda Joosen; Ying Dunkel; Nina Sun; Peter Nguyen; Deepali Bhandari
Journal:  Curr Protoc Chem Biol       Date:  2016-12-07

4.  Met kinase-dependent loss of the E3 ligase Cbl in gastric cancer.

Authors:  Andrea Z Lai; Michael Durrant; Dongmei Zuo; Colin D H Ratcliffe; Morag Park
Journal:  J Biol Chem       Date:  2012-01-18       Impact factor: 5.157

5.  Regulation of epidermal growth factor receptor ubiquitination and trafficking by the USP8·STAM complex.

Authors:  Ilana Berlin; Heather Schwartz; Piers D Nash
Journal:  J Biol Chem       Date:  2010-08-24       Impact factor: 5.157

6.  An E3 ubiquitin ligase: c-Cbl: a new therapeutic target of lung cancer.

Authors:  Fang-Yi Lo; Yi-Hung Carol Tan; Hung-Chi Cheng; Ravi Salgia; Yi-Ching Wang
Journal:  Cancer       Date:  2011-05-23       Impact factor: 6.860

7.  Spry1 as a novel regulator of erythropoiesis, EPO/EPOR target, and suppressor of JAK2.

Authors:  Pradeep Sathyanarayana; Arvind Dev; Anamika Pradeep; Melanie Ufkin; Jonathan D Licht; Don M Wojchowski
Journal:  Blood       Date:  2012-04-16       Impact factor: 22.113

8.  c-Cbl inhibition improves cardiac function and survival in response to myocardial ischemia.

Authors:  Khadija Rafiq; Mikhail A Kolpakov; Rachid Seqqat; Jianfen Guo; Xinji Guo; Zhao Qi; Daohai Yu; Bhopal Mohapatra; Neha Zutshi; Wei An; Hamid Band; Archana Sanjay; Steven R Houser; Abdelkarim Sabri
Journal:  Circulation       Date:  2014-02-28       Impact factor: 29.690

9.  Down-regulation of c-Cbl by morphine accounts for persistent ERK1/2 signaling in delta-opioid receptor-expressing HEK293 cells.

Authors:  Daniela A Eisinger; Hermann Ammer
Journal:  J Biol Chem       Date:  2009-10-14       Impact factor: 5.157

10.  Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src.

Authors:  Byung Min Chung; Srikumar M Raja; Robert J Clubb; Chun Tu; Manju George; Vimla Band; Hamid Band
Journal:  BMC Cell Biol       Date:  2009-11-30       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.